Propanc Biopharma Enters into Research Collaboration Agreement with the University of Jaén

On Sep 20, 2018

Propanc Biopharma announced the execution of a research collaboration agreement with the University of Jaén, Spain, for the provision of research services and scientific technical advice for the Company’s POP1 drug discovery program. The goal for the program is to synthesize and develop a backup clinical compound to the Company’s lead product candidate, PRP. The development of the backup compound will be used for treating patients with limited therapeutic options for the treatment of solid tumors,

The specific objectives for the collaboration include:

The identification of a suitable backup clinical compound to PRP;
The validation of the anti-carcinogenic properties of the new drug candidate through in vitro testing;
The validation of the anti-carcinogenic properties of the new drug candidate through in vivo testing;
The production of the new synthetic drug candidate in compliance with FDA’s “current good manufacturing practice” (cGMP) conditions, in order for it to be used in human trials.

Dr. Macarena Perán Quesada, Professor at the University of Jaén, will be in charge of management and coordination of the working team and will be the scientific consultant in charge of the project run by the University of Jaén. Dr. Perán is the lead author of several scientific papers jointly published with the Company regarding the anti-cancer and anti-tumor effects of PRP, as well as a co-inventor of several patents in the Company’s intellectual property portfolio, including the discovery of PRP as a targeted, cancer stem cell therapy.

“We are truly delighted to be working with Dr. Perán, as we look to discover and develop new compounds which support our lead product candidate, PRP, which is progressing towards human trials,” said Mr. James Nathanielsz, Propanc Biopharma’s Chief Executive Officer. “Our vision is to establish a new therapeutic drug class for the treatment and prevention of metastatic cancer, by targeting and eradicating cancer stem cells. We look forward to executing this important project with Dr. Perán and the Department of Health Sciences at the University of Jaén.”

“The collaboration between public institutions and biotech companies is key to overcoming therapeutic challenges,” said Dr. Perán. “We are excited to commence this new project with the hope of providing an effective treatment against aggressive cancers, like pancreatic cancer.”